Pulmatrix, Inc. last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.29. It usually reports 16–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Oct 15, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Oct 16, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 16–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-1
+33.1%
|
-0.29
+31.0%
|
|
May 15, 2026
45 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-1
+35.2%
|
-0.32
+36.0%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-1
+53.3%
|
-0.25
+53.3%
|
|
Oct 16, 2025
16 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-1
+66.1%
|
-0.24
+66.2%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-2
+73.3%
|
-0.42
+73.6%
|
|
Nov 8, 2024
39 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
0
-79.1%
|
-3
+31.5%
|
-0.71
+31.1%
|
|
Aug 13, 2024
44 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 10, 2024
40 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PULM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Framingham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1574235
- Former names
- Ruthigen, Inc. (until Jun 16, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.